Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2024

Open Access 01-12-2024 | COVID-19 | Research

Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials

Authors: Mauricia Davidson, Theodoros Evrenoglou, Carolina Graña, Anna Chaimani, Isabelle Boutron

Published in: BMC Medical Research Methodology | Issue 1/2024

Login to get access

Abstract

Background

Preprints are increasingly used to disseminate research results, providing multiple sources of information for the same study. We assessed the consistency in effect estimates between preprint and subsequent journal article of COVID-19 randomized controlled trials.

Methods

The study utilized data from the COVID-NMA living systematic review of pharmacological treatments for COVID-19 (covid-nma.com) up to July 20, 2022. We identified randomized controlled trials (RCTs) evaluating pharmacological treatments vs. standard of care/placebo for patients with COVID-19 that were originally posted as preprints and subsequently published as journal articles. Trials that did not report the same analysis in both documents were excluded. Data were extracted independently by pairs of researchers with consensus to resolve disagreements. Effect estimates extracted from the first preprint were compared to effect estimates from the journal article.

Results

The search identified 135 RCTs originally posted as a preprint and subsequently published as a journal article. We excluded 26 RCTs that did not meet the eligibility criteria, of which 13 RCTs reported an interim analysis in the preprint and a final analysis in the journal article. Overall, 109 preprint–article RCTs were included in the analysis. The median (interquartile range) delay between preprint and journal article was 121 (73–187) days, the median sample size was 150 (71–464) participants, 76% of RCTs had been prospectively registered, 60% received industry or mixed funding, 72% were multicentric trials. The overall risk of bias was rated as ‘some concern’ for 80% of RCTs. We found that 81 preprint–article pairs of RCTs were consistent for all outcomes reported. There were nine RCTs with at least one outcome with a discrepancy in the number of participants with outcome events or the number of participants analyzed, which yielded a minor change in the estimate of the effect. Furthermore, six RCTs had at least one outcome missing in the journal article and 14 RCTs had at least one outcome added in the journal article compared to the preprint. There was a change in the direction of effect in one RCT. No changes in statistical significance or conclusions were found.

Conclusions

Effect estimates were generally consistent between COVID-19 preprints and subsequent journal articles. The main results and interpretation did not change in any trial. Nevertheless, some outcomes were added and deleted in some journal articles.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kirkham JJ, Penfold NC, Murphy F, Boutron I, Ioannidis JP, Polka J, et al. Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. BMJ Open. 2020;10(12):e041849.CrossRefPubMedPubMedCentral Kirkham JJ, Penfold NC, Murphy F, Boutron I, Ioannidis JP, Polka J, et al. Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. BMJ Open. 2020;10(12):e041849.CrossRefPubMedPubMedCentral
2.
go back to reference Kwon D. How swamped preprint servers are blocking bad coronavirus research. Nature. 2020;581(7807):130–1.CrossRefPubMed Kwon D. How swamped preprint servers are blocking bad coronavirus research. Nature. 2020;581(7807):130–1.CrossRefPubMed
5.
go back to reference Flanagin A, Fontanarosa PB, Bauchner H. Preprints involving medical research—do the benefits outweigh the challenges? JAMA. 2020;324(18):1840–3.CrossRefPubMed Flanagin A, Fontanarosa PB, Bauchner H. Preprints involving medical research—do the benefits outweigh the challenges? JAMA. 2020;324(18):1840–3.CrossRefPubMed
6.
go back to reference van Schalkwyk MCI, Hird TR, Maani N, Petticrew M, Gilmore AB. The perils of preprints. BMJ. 2020;370:m3111.CrossRefPubMed van Schalkwyk MCI, Hird TR, Maani N, Petticrew M, Gilmore AB. The perils of preprints. BMJ. 2020;370:m3111.CrossRefPubMed
7.
go back to reference Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, the COVID-19 NMA Consortium. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Med. 2020;18(1):402.CrossRefPubMedPubMedCentral Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, the COVID-19 NMA Consortium. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Med. 2020;18(1):402.CrossRefPubMedPubMedCentral
8.
go back to reference Kapp P, Esmail L, Ghosn L, Ravaud P, Boutron I. Transparency and reporting characteristics of COVID-19 randomized controlled trials. BMC Med. 2022;20(1):363.CrossRefPubMedPubMedCentral Kapp P, Esmail L, Ghosn L, Ravaud P, Boutron I. Transparency and reporting characteristics of COVID-19 randomized controlled trials. BMC Med. 2022;20(1):363.CrossRefPubMedPubMedCentral
9.
go back to reference Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, et al. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. BMJ Open. 2021;11(7):e051821.CrossRefPubMed Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, et al. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. BMJ Open. 2021;11(7):e051821.CrossRefPubMed
11.
go back to reference Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D, Rada G, et al. The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic. Ann Intern Med. 2020;173(12):1015–7.CrossRefPubMed Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D, Rada G, et al. The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic. Ann Intern Med. 2020;173(12):1015–7.CrossRefPubMed
16.
go back to reference Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.CrossRefPubMed Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.CrossRefPubMed
17.
18.
go back to reference Viechtbauer W. Conducting Meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48.CrossRef Viechtbauer W. Conducting Meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48.CrossRef
21.
go back to reference Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Casirivimab and Imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2022;399(10325):665–76.CrossRef Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Casirivimab and Imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2022;399(10325):665–76.CrossRef
22.
go back to reference Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalised COVID-19 patients: a randomized double-blind clinical trial (DISCOVER) [Internet]. Rochester, NY; 2021 [cited 2022 Nov 21]. Available from: https://papers.ssrn.com/abstract=3792895. Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalised COVID-19 patients: a randomized double-blind clinical trial (DISCOVER) [Internet]. Rochester, NY; 2021 [cited 2022 Nov 21]. Available from: https://​papers.​ssrn.​com/​abstract=​3792895.
23.
go back to reference Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother. 2022;77(3):758–66.CrossRefPubMed Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother. 2022;77(3):758–66.CrossRefPubMed
25.
go back to reference Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet. 2021;397(10289):2049–59.CrossRef Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet. 2021;397(10289):2049–59.CrossRef
27.
go back to reference Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care. 2021;11(1):5.CrossRefPubMedPubMedCentral Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care. 2021;11(1):5.CrossRefPubMedPubMedCentral
29.
go back to reference Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a Randomized Clinical Trial. JAMA. 2021;325(11):1053–60.CrossRefPubMed Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a Randomized Clinical Trial. JAMA. 2021;325(11):1053–60.CrossRefPubMed
31.
go back to reference Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, et al. Lenzilumab in hospitalised patients with COVID-19 Pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(3):237–46.CrossRefPubMed Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, et al. Lenzilumab in hospitalised patients with COVID-19 Pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(3):237–46.CrossRefPubMed
33.
go back to reference Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752–60.CrossRefPubMedPubMedCentral Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752–60.CrossRefPubMedPubMedCentral
35.
go back to reference Quinn TM, Gaughan EE, Bruce A, Antonelli J, O’Connor R, Li F et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b/2a experimental study to investigate safety. Pharmacokinet Pharmacodynamics eBioMedicine. 2022;76. Quinn TM, Gaughan EE, Bruce A, Antonelli J, O’Connor R, Li F et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b/2a experimental study to investigate safety. Pharmacokinet Pharmacodynamics eBioMedicine. 2022;76.
37.
go back to reference Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early Outpatient Treatment for Covid-19 with Convalescent plasma. N Engl J Med. 2022;386(18):1700–11.CrossRefPubMed Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early Outpatient Treatment for Covid-19 with Convalescent plasma. N Engl J Med. 2022;386(18):1700–11.CrossRefPubMed
38.
go back to reference Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.CrossRefPubMed Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.CrossRefPubMed
39.
go back to reference Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:n949.CrossRefPubMed Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:n949.CrossRefPubMed
40.
go back to reference Eckmann P, Bandrowski A, PreprintMatch. A tool for preprint to publication detection shows global inequities in scientific publication. PLoS ONE. 2023;18(3):e0281659.CrossRefPubMedPubMedCentral Eckmann P, Bandrowski A, PreprintMatch. A tool for preprint to publication detection shows global inequities in scientific publication. PLoS ONE. 2023;18(3):e0281659.CrossRefPubMedPubMedCentral
41.
go back to reference Brietzke E, Gomes FA, Gerchman F, Freire RCR. Should systematic reviews and meta-analyses include data from preprints? Trends Psychiatry Psychother 45:e20210324. Brietzke E, Gomes FA, Gerchman F, Freire RCR. Should systematic reviews and meta-analyses include data from preprints? Trends Psychiatry Psychother 45:e20210324.
42.
go back to reference Davidson M, Evrenoglou T, Graña C, Chaimani A, Boutron I. No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study. J Clin Epidemiol. 2023;162:90–7.CrossRefPubMed Davidson M, Evrenoglou T, Graña C, Chaimani A, Boutron I. No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study. J Clin Epidemiol. 2023;162:90–7.CrossRefPubMed
43.
go back to reference Carneiro CFD, Queiroz VGS, Moulin TC, Carvalho CAM, Haas CB, Rayêe D, et al. Comparing quality of reporting between preprints and peer-reviewed articles in the biomedical literature. Res Integr Peer Rev. 2020;5(1):16.CrossRefPubMedPubMedCentral Carneiro CFD, Queiroz VGS, Moulin TC, Carvalho CAM, Haas CB, Rayêe D, et al. Comparing quality of reporting between preprints and peer-reviewed articles in the biomedical literature. Res Integr Peer Rev. 2020;5(1):16.CrossRefPubMedPubMedCentral
44.
go back to reference Brierley L, Nanni F, Polka JK, Dey G, Pálfy M, Fraser N, et al. Tracking changes between preprint posting and journal publication during a pandemic. PLOS Biol. 2022;20(2):e3001285.CrossRefPubMedPubMedCentral Brierley L, Nanni F, Polka JK, Dey G, Pálfy M, Fraser N, et al. Tracking changes between preprint posting and journal publication during a pandemic. PLOS Biol. 2022;20(2):e3001285.CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials
Authors
Mauricia Davidson
Theodoros Evrenoglou
Carolina Graña
Anna Chaimani
Isabelle Boutron
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Medical Research Methodology / Issue 1/2024
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-023-02136-8

Other articles of this Issue 1/2024

BMC Medical Research Methodology 1/2024 Go to the issue